REPL Research and Charts

REPL - Replimune Group Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-05-09 (Delayed quote data 2026-02-10)

Last 7.80	Change ⇑ +0.02 (+0.26%)	Volume 894,588
	Open 7.57	High 7.93	Low 7.57

8EMA (Daily) 7.50	40EMA (Daily) 8.03	50EMA (Daily) 8.11	STO (Daily) 59.473	MACD Hist (Daily) 0.164
8EMA (Weekly) 7.969	40EMA (Weekly) 8.29	50EMA (Weekly) 8.50	STO (Weekly) 22.172	MACD Hist (Weekly) -0.269


Company Profile
Replimune Group Inc is a clinical-stage biotechnology company. Its use a proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. The company's pipeline products include RP1, RP2, and RP3.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.